Wendye Robbins

Wendye Robbins serves as the President and Chief Executive Officer at Incendia Therapeutics, a clinical stage company focused on drugging novel targets within the tumor micro-environment, since June 2023. Additionally, Robbins holds a position on the Board of Directors at RAPT Therapeutics, contributing to the Audit, Transaction, and Pricing Committees. Prior roles include being a Board Of Trustees member at the Buck Institute for Research on Aging and a Board Of Directors member at the California Life Sciences Association between January 2019 and May 2023. As the former President and CEO of Blade Therapeutics, Robbins oversaw the translational strategy and successfully raised $145 million in funding. Academic contributions include a Clinical Associate Professor role at Stanford University School of Medicine. Educational credentials include an MD from The Medical College of Pennsylvania and extensive training in internal medicine and anesthesiology from prestigious institutions.